The Effect of Serum LDL Lowering on Aspirin Resistance

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Aspirin resistance is the persistent platelet activation, demonstrated by platelet function tests (1).

The hypothesis is that:LDL lowering by statin in patients with aspirin resistance can improve the effect of aspirin due to the potential decreasing of cholesterol content in the platelet membranes.

Patients and methods:Forty hypercholesterolemic patients with aspirin resistance after 5 days of treatment with aspirin and high LDL and triglycerides<300 mg/dL, will be enrolled.

Ten healthy volunteers will be the control group.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ziv Hospital
• Treatments: Aspirin

Criteria

Inclusion Criteria:

1. Hypercholesterolemic low-moderate risk patients without hypolipidemic drugs for at least one month.

2. Age ≥18 years on stable AHA step 1 diet.

3. For primary prevention, LDL > 130 mg/dL and for secondary prevention LDL>70 and <100mg/dL. .

4. CPK, ALT and AST < 1.5 x upper limit of normal at baseline.

Exclusion Criteria:

1. Women currently receiving cyclical hormones.

2. Treatment with hypolipidemic drugs during the last month.

3. Oral corticosteroids, NSAID, COX-1 inhibitors and other antiplatelet drugs.

4. Women with childbearing potential unless on safe contraception.

5. Psychiatric disease with defect in judgement.

6. Severe renal or hepatic diease.

7. Uncontrolled hypo- or hyperthyroidism.

8. Contraindication for ezetimibe or statin treatment.